Versant Venture Capital VI, L.P. 13D and 13G filings for Aligos Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-08 5:44 pm Unchanged | 2023-11-02 | 13D | Aligos Therapeutics, Inc. ALGS | Versant Venture Capital VI, L.P. | 58,317 1.900% | 0 (Unchanged) | Filing |
| 2021-06-21 4:44 pm Sale | 2021-06-11 | 13D | Aligos Therapeutics, Inc. ALGS | Versant Venture Capital VI, L.P. | 58,317 3.800% | -19,439 (-25.00%) | Filing |
| 2021-05-03 4:57 pm Sale | 2021-04-26 | 13D | Aligos Therapeutics, Inc. ALGS | Versant Venture Capital VI, L.P. | 77,757 5.100% | -19,439 (-20.00%) | Filing |
| 2020-10-30 4:25 pm Purchase | 2020-10-20 | 13D | Aligos Therapeutics, Inc. ALGS | Versant Venture Capital VI, L.P. | 97,196 7.200% | 97,196 (New Position) | Filing |